<DOC>
	<DOCNO>NCT00767598</DOCNO>
	<brief_summary>In order evaluate effect CYP3A5*3 allele pharmacokinetics sildenafil , udenafil , vardenafil , clinical trial use single oral dose conducted Korean healthy male subject whose genotype CYP3A5 determine .</brief_summary>
	<brief_title>The Effect CYP3A Genetic Polymorphism Pharmacokinetics Phosphodiesterase type5 Inhibitors Male Subjects</brief_title>
	<detailed_description>The aim study evaluate different effect CYP3A5 genotype pharmacokinetics ( PK ) sildenafil , udenafil , vardenafil healthy male subject . Twenty one healthy male subject CYP3A5*1/*1 , *1/*3 , *3/*3 enrol . An open-label 3-way crossover study perform week washout . A single oral dose PDE5I ( 100 mg sildenafil ; 200 mg udenafil ; 20 mg vardenafil ) administer , respectively . After single oral dose phosphodiesterase type 5 inhibitor ( PDE5I ) , plasma level parent major metabolite measure 24 48 h .</detailed_description>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Healthy male subject whose CYP3A5 genotype determine Subject whose CYP3A5 genotype determine</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>CYP3A5</keyword>
	<keyword>sildenafil</keyword>
	<keyword>udenafil</keyword>
	<keyword>vardenafil</keyword>
</DOC>